Tumor migration has also been proven to be potentially related to the nuclear translocation of PD-L1, and nuclear PD-L1 also triggers the expressions of other immune checkpoint molecules that are not targeted by PD-1/PD-L1 blockade, leading to possible acquired immunotherapy resistance. The gene discussed is PDCD1; the disease is neoplasm.